Starpharma Holdings Stock

Starpharma Holdings EBIT Margin

The EBIT Margin (Operating Margin) of Starpharma Holdings (SPL.AX) as of Aug 12, 2026 is -170.77 %. In the previous year, EBIT Margin (Operating Margin) was -83.69 % — a change of 104.04% (lower).

EBIT Margin

-170.77 %

YoY

104.04%

Last updated:

EBIT Margin (Operating Margin) of Starpharma Holdings is 2026 -170.77 % . EBIT Margin (Operating Margin) of Starpharma Holdings was 2025 -83.69 % . It decreases by 104.04% lower compared to the previous year.

For Starpharma Holdings, the operating (EBIT) margin of -170.8% is up versus -979.5% a few years ago.

Access this data via the Eulerpool API

Starpharma Holdings Stock analysis

What does Starpharma Holdings do? Starpharma Holdings Ltd is an Australian company specializing in the development of innovative solutions in the fields of pharmacy and biotechnology. The company was founded in 1996 and has since written an impressive history full of successful developments and numerous partnerships. The main business of Starpharma focuses on the development and commercialization of drugs and other health products based on dendrimer technology. One of the most advanced applications of dendrimer technology is VivaGel, a topical gel for the prevention of sexually transmitted diseases, particularly HPV (Human Papillomavirus). VivaGel is based on a dendrimer that acts both as an antiviral agent and an antibiotic, capable of preventing infection by different types of HPV. The product has already undergone Phase III clinical trials and is currently being marketed worldwide. In addition to VivaGel, Starpharma also offers dendrimer-based technologies and services in the field of drug development. The company has formed numerous partnerships with major pharmaceutical companies such as AstraZeneca, GSK, and Merck, and is involved in the development of drugs for cancer, autoimmune diseases, and infectious diseases. Furthermore, Starpharma has expanded its dendrimer technology to other industries, such as agriculture, where dendrimers can contribute to improving soil quality and reducing pesticide use. In this sector, Starpharma has also formed partnerships with agricultural companies such as Adama and Nufarm. Overall, Starpharma is a company that has experienced significant growth in recent years and continues to focus on the development of new and innovative products and solutions. Its core competence in dendrimer technology has allowed it to establish itself as a key player in various industries and build numerous partnerships with global companies. With its diverse range of products and services and a strong focus on research and development, Starpharma can be considered an important player in the field of biotechnology and healthcare innovations. Indicate the sector in starpharma specialize in. Starpharma Holdings is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Starpharma Holdings stock

EBIT Margin (Operating Margin) of Starpharma Holdings is -170.77 % in 2026.

EBIT Margin (Operating Margin) of Starpharma Holdings changed from -83.69 % to -170.77 %, representing a 104.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Starpharma Holdings since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Starpharma Holdings with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

Margins — Starpharma Holdings

All Key Metrics — Starpharma Holdings